Article
Citigroup Maintains Buy on Medline, Raises Price Target to $60
Citigroup analyst Patrick Donnelly maintains Medline (NASDAQ:MDLN) with a Buy and raises the price target from $48 to $60.
Comments
- No comments yet. Be the first to comment!